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Summary: We report seven novel mutations, including three amino acids substitutions
(p.Glu286Lys, p.Cys560Tyr, p.Pro615Leu), two nonsense mutations (p.Arg31X, p.Glu
451X), one splicing defect (c.2125−1G>A), one small deletion (c.1758–1759delA)
and nine previously described mutations identified in 10 unrelated Italian patients
affected by mut MMA.
Mutations in the MUT gene, encoding mitochondrial methylmalonyl-CoA mutase (MCM)
(EC 5.4.99.2), give rise to mut methylmalonic aciduria (mut MMA) (McKusick 251000).
Mut MMA shows a wide clinical spectrum, ranging from severe acute neonatal onset and
early death to late-onset mild forms. Two biochemical phenotypes have been reported: mut0
with no detectable enzymatic activity and mut− with residual activity. The mature MCM is
organized in a barrel domain with the CoA-binding site, a cobalamin-binding domain and
a linker region.
This study includes 10 unrelated Italian patients affected by mut MMA. Seven patients
presented a neonatal onset and three showed the first symptoms between 3 months and
2 years of age. Diagnosis of MMA was performed by plasma amino acids and GC–
MS urinary organic acids analyses. Complementation analysis, MCM activity assay and
[14C]propionate incorporation test with and without hydroxocobalamin (OHCbl) added to
the culture medium were carried out in eight available patient fibroblast lines by Professor
D.S. Rosenblatt (McGill University, Montreal Quebec, Canada; patients 2 and 6), Dr. J.F.
Benoist (Robert Debre Hospital, Paris, France; patient 3) and Dr R. Baumgartner (Univer-
sity Children’s Hospital, Basel, Switzerland; patients 1, 7, 8, 9 and 10). Complementation
analysis and deficient MCM enzyme activity proved mut MMA in all patients. A very low
uptake of [14C]propionate, not responsive to OHCbl supplementation in the medium, clas-
sified six patients as mut0. Two patients showed the typical mut− phenotype, with a slight
stimulation of [14C]propionate incorporation in presence of OHCbl.
Mutation analysis was performed by direct sequencing of genomic DNA and/or total
RNA isolated from peripheral blood.
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Seven new mutations and nine previously reported mutations were detected (Table 1). In
order to exclude the possibility of a benign polymorphism for the newly identified missense
mutations, specific restriction analyses were carried out on 100 control gDNAs.
The new heterozygous c.856G>A and c.1351G>T changes, leading to substitution of
glutamate by a lysine (p.Glu286Lys) and a stop codon (p.Glu451X), were identified in patient
1. She was affected by mut− MMA and had experienced only two acute metabolic crises
before diagnosis, made at the age of 2 years. She is presently 21 years old and doing well.
The p.Glu286Lys and p.Glu451X mutations map in the barrel domain and linker region,
respectively. Since the p.Glu451X mutation leads to a truncated protein, containing only the
barrel domain, the patient’s mild clinical phenotype can be correlated to the p.Glu286Lys.
Glu286 is a moderately conserved acid residue and its replacement with a basic codon may
slightly affect the function of MCM.
In patient 2, affected by severe mut0 MMA, who died during a metabolic crisis at the
age of 6 years, the new c.1679G>A (p.Cys560Tyr) and c.2125−1G>A substitutions were
identified. The c.1679G>A (p.Cys560Tyr) was detected as a homozygous change at cDNA
level and as heterozygous in gDNA. This amino acid change involves a highly conserved
residue of the linker region and it could alter the structural stability of MCM protein. Up
to now, 11 known mutations mapping in the MCM linker region have been reported, but
only the new p.Cys560Tyr and the known p.Ala535Pro (Fuchshuber et al 2000) are amino
acid substitutions. Interestingly, in patient 2 the second c.2125−1G>A mutation was only
revealed in genomic DNA. No aberrant transcript was detected in the agarose gel when we
analysed the cDNA PCR products. Such a mutation affects the acceptor splicing site of the
last exon (exon 13) of the MUT gene, and this could explain the non-detection of any extra
band in cDNA, synthesized by oligo-dT and specific 3′ UTR primers and amplified using
the specific 3′ UTR primer. Thus, the importance of a combined analysis on cDNA and
gDNA should be stressed. In this patient, the pathogenic effect of such mutations proved
consistent with the mut0 phenotype determined biochemically.
The novel c.1844C>T transition, leading to p.Pro615Leu in the cobalamin-binding do-
main, and the known p.Ser262Asn, were identified in patient 3. A mutation affecting the
same 615 codon (p.Pro615Thr) has been reported in a mut0 patient and incorrect protein
folding, resulting in an alterated cobalamin-binding domain function, was hypothesized
(Peters et al 2002). Since the p.Ser262Asn mutation was previously correlated to mut0 pa-
tients and our patient 3 (p.Pro615Leu/p.Ser262Asn compound) showed a mut− phenotype,
it can be speculated that the p.Pro615Leu mutation associates with the mut− phenotype.
The new c.91C>T transition, introducing an early termination codon p.Arg31X within
the mitochondrial target sequence, and the p.Arg108His change were identified in patient
4. The p.Arg108His and the new c.1758–1759delA were identified in patient 5. The latter
small deletion, causing a frameshift with an early stop codon (p.Ala586fsX597), leads
to a protein lacking the cobalamin-binding domain. Since the p.Arg108His change was
correlated to the mut0 phenotype (Acquaviva et al 2005) and both patients 4 and 5 are
compound heterozygous for the p.Arg108His and a null allele, a mut0 phenotype can be
hypothesized also for them.
The known p.Asn219Tyr mutation was detected in three of our patients (20% of the
screened alleles), confirming it to be a frequent mutation among Caucasian mut0 MMA pa-
tients as previously reported by Acquaviva and colleagues (2001). Patient 8 was homozygous
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for the p.Asn219Tyr amino acid change but, unfortunately, the possibility of a partial or
complete deletion of the patient’s MUT gene cannot be ruled out owing to the unavailability
of her parents’ DNA.
In conclusion, molecular analysis provides a reliable tool in confirming diagnosis of
the proband, identifying carrier status and performing early prenatal diagnosis, and this
study may contribute to increased knowledge about the spectrum of mutations leading to
methylmalonyl-CoA mutase deficiency.
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